Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy forHelicobacter pylorieradication

2014 ◽  
Vol 23 (5) ◽  
pp. 443-455 ◽  
Author(s):  
Chen-Li Ye ◽  
Guo-Ping Liao ◽  
Shuai He ◽  
Yan-Na Pan ◽  
Ying-Bo Kang ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Triple Therapy ◽  
Proton Pump ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Peptic ulcer recurrence during maintenance therapy with H 2 -receptor antagonist following first-line therapy with proton pump inhibitor

2000 ◽  
Vol 35 (11) ◽  
pp. 824-831 ◽  
Author(s):  
Eizo Kaneko ◽  
Yoshio Hoshihara ◽  
Nobuhiro Sakaki ◽  
Shigeru Harasawa ◽  
Kiyoshi Ashida ◽  
...  
Keyword(s):  
Peptic Ulcer ◽  
Proton Pump Inhibitor ◽  
Maintenance Therapy ◽  
Receptor Antagonist ◽  
Proton Pump ◽  
Ulcer Recurrence ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Is It Time for Quadruple Therapy to be First Line?

2003 ◽  
Vol 17 (suppl b) ◽  
pp. 33B-35B ◽  
Author(s):  
Loren Laine
Keyword(s):  
Triple Therapy ◽  
Randomized Trials ◽  
Eradication Rate ◽  
First Line ◽  
Quadruple Therapy ◽  
First Line Therapy ◽  
Clarithromycin Resistance ◽  
Line Therapy ◽  
Metronidazole Resistance ◽  
H Pylori

The most commonly used regimen forHelicobacter pyloritherapy at present is twice-daily proton pump inhibitor (PPI)-based triple therapy. Bismuth-based therapy is the next most common treatment used by gastroenterologists. When a PPI is combined with bismuth-based triple therapy (quadruple therapy), eradication rates are increased as compared with the triple therapy alone. Three separate randomized trials from three continents that compare quadruple therapy and PPIbased triple therapy revealed remarkably similar results. Eradication rates with PPI-based triple therapy and quadruple therapy were not significantly different. The eradication rates with quadruple therapy were 3% to 6% higher than PPI triple therapy, indicating that quadruple therapy should be no less effective than PPI triple therapy. Furthermore, these two therapies had similar rates of compliance and adverse events.The major potential benefit of the quadruple therapy relates to antibiotic resistance. In patients with clarithromycin resistance, PPIbased triple therapy, but not quadruple therapy, had a significantly lower eradication rate. However, due to its ability to largely overcome metronidazole resistance, quadruple therapy had little if any decrement in eradication rates compared with PPI triple therapy in patients with metronidazole-resistantH pylori. Therefore, quadruple therapy can be considered a first line therapy forH pylori.

scholarly journals Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin

2010 ◽  
Vol 47 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Makoto Sasaki ◽  
Naotaka Ogasawara ◽  
Keiko Utsumi ◽  
Naohiko Kawamura ◽  
Tskeshi Kamiya ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Proton Pump Inhibitor ◽  
Triple Therapy ◽  
Proton Pump ◽  
Eradication Rate ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document